Amfetamine extended-release - Tris Pharma

Drug Profile

Amfetamine extended-release - Tris Pharma

Alternative Names: Amfetamine XR - Tris Pharma; DyanavelXR; TRI 102

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tris Pharma
  • Class Amphetamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Diabetes mellitus

Most Recent Events

  • 11 Feb 2017 Tris Pharma initiates enrolment in a phase III trial for Attention-deficit hyperactivity disorder (In children) in USA (NCT03088267)
  • 09 Feb 2017 The approved US label for Amfetamine extended release - Tris Pharma carries a black box warning related to abuse and dependence
  • 09 Feb 2017 Adverse events and efficacy data from a phase III trial in Attention-deficit hyperactivity disorder released by Tris Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top